Weekly Twitter Roundup
Posted by Dan Vorhaus on January 22, 2010
Each week there are a number of stories and developments that, for one reason or another, don’t find their way into a full-length posting on the Genomics Law Report. Here’s a recap of what I was Tweeting this week @genomicslawyer:
- Australia Issues New Privacy Guidelines for Health Practitioners on Disclosing Genetic Information w/o Patient Consent: http://bit.ly/4GKqkK
- Agenda for next SACGHS meeting now online: http://bit.ly/5J5qfF On tap: Gene Patent and Licensing Recs, Genomic Data Sharing Models, etc.
- NIST awards EHR testing contract, ONC seeks to re-identify HIPAA data: http://bit.ly/86LZ8R (via FierceHealthIT)
- Ireland’s new criminal DNA database raises familiar privacy concerns: http://bit.ly/7UfHyQ
- Summary judgment args in Myriad/ACLU gene patent case were supposed to be heard today. Postponed until 2/2. Nobody said this would be quick.
- Last tweet: @decodegenetics “plans to begin whole genome seq. of 2500 DNA samples from its database.” Which database? deCODEme?
- RT @ScienceInsider: @decodegenetics Rises From the Ashes http://bit.ly/8OdlI9
- CER vs. Pharma battle in Germany turns political. A sign of things to come in the US? http://bit.ly/82XNK2 (via @ScienceInsider)
- RT @bigs: Powerful. @edyson uses Gutenberg bible analogy for why direct-to-consumer data will win vs the cloistered medical priesthood #pmwc
- Personalized Medicine: The Case for Diagnostics Focuses on Cost and Effectiveness: http://bit.ly/6RGSoc (from @crossborderbio)
- RT @chiah: My first post on the @techpulse360 blog! Genetics and pharmacogenomics Take Center Stage at #pmwc. http://bit.ly/8hPdOJ
- Still on FDA’s Table: IVDMIAs, Rx/Dx Co-development, 510(k) Process, Promotion of Research-Use Dx: http://bit.ly/8D1fhN (via PGx Reporter)
- GLR Update: In the Battle for Sequencing Supremacy, is 128 > $10,000? http://bit.ly/5xCiIn
- GLR Update: The Fate of Follow-On Biologics Remains Uncertain: http://bit.ly/5CSwta
- RT @crossborderbio: RT @FierceBiotech: Expert advice: Biotech VC trends to watch in 2010. http://is.gd/6FlY0
- RT @chiah: “The question is what kind of quality genome you get, not the cost of the genome. Is it 25% or 99.99% accurate?” Dr. Greely #pmwc
- RT @mza: The Genome Analysis Toolkit, a map/reduce framework from the Broad Institute. Very cool: http://bit.ly/5PBhKk (HT @jandot)
- Analysts improve Affymetrix short-term stock outlook; remain “highly cautious” due to “fierce competition.” http://bit.ly/8dSCkE
- RT @BiotechPatent: Governors protest Obama’s move on generic drugs – The Hill’s Blog Briefing Room: http://bit.ly/4MqVWB
- RT @Knome: What does Xconomy have to say about Knome? See their interview with Knome CEO Jorge Conde: http://tinyurl.com/ycx5wpj
- Wide-ranging interview-synthetic bio, PGP, etc-w/ George Church in Bulletin of the Atomic Scientists http://bit.ly/7St3M1
- RT @chiah: Elizabeth Mansfield, FDA “Policies not written w/ personalized medicine in mind. We are trying find best pathway forward.” #pmwc
- From Bench to Market: The License-Out as a Business Model: http://bit.ly/68ZNUl
- RT @nutrigenomics: Illumina CEO Says Next Round of GWAS Will Be Done on Arrays, Not Sequencers http://bit.ly/5kh5fQ
- RT @EdwardWinstead: Analysis of JPM healthcare conf by @lindaavey: Gene patents (BRCA) v cheap genomes http://bit.ly/5Jbpn0
- RT @NatureNews: Biotech drug database goes public http://ff.im/-ex5oH
- Investors (Arch & Polaris) Spring @decodegenetics from Chapter 11 Bankruptcy: http://bit.ly/8AuUWK (via @Ryan_McBride) Only $14M
- RT @crossborderbio: Told you it wasn’t over. Obama mounts fight against 12 years of data exclusivity http://viigo.im/25qZ
- RT @dgmacarthur: RT @decodegenetics: The opportunity to migrate to deCODEme ends on February 1st 2010. http://bit.ly/86Xtsh
